Launay-Vacher V - Search Results

1

Colony stimulating factors (CSF) biosimilars. Progress?

Scotté F, Launay-Vacher V, Rey JB. Scotté F, et al. Target Oncol. 2012 Mar;7 Suppl 1:S17-24. doi: 10.1007/s11523-011-0189-2. Epub 2012 Jan 17. Target Oncol. 2012. PMID: 22249656 Review.

2

Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.

Rey JB, Launay-Vacher V, Tournigand C. Rey JB, et al. Target Oncol. 2015 Jun;10(2):199-213. doi: 10.1007/s11523-014-0333-x. Epub 2014 Sep 12. Target Oncol. 2015. PMID: 25213039 Free PMC article. Review.

3

[Iron deficiency and anemia in oncology].

Scotté F, Launay-Vacher V, Ray-Coquard I. Scotté F, et al. Bull Cancer. 2012 May;99(5):563-70. doi: 10.1684/bdc.2012.1579. Bull Cancer. 2012. PMID: 22516641 French.

4

Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads.

Scotté F, Rey JB, Launay-Vacher V. Scotté F, et al. Support Care Cancer. 2012 Dec;20(12):3033-42. doi: 10.1007/s00520-012-1590-9. Epub 2012 Sep 9. Support Care Cancer. 2012. PMID: 22960941 Review.

5

Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey.

Janus N, Scotte F, Rey JB, Amet S, Rouillon L, Zakin L, Mahi L, Deray G, Launay-Vacher V. Janus N, et al. Support Care Cancer. 2013 Oct;21(10):2743-8. doi: 10.1007/s00520-013-1845-0. Epub 2013 May 29. Support Care Cancer. 2013. PMID: 23715817

6

Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France.

Launay-Vacher V, Janus N, Deray G, Scotté F. Launay-Vacher V, et al. Support Care Cancer. 2016 Aug;24(8):3347-51. doi: 10.1007/s00520-016-3162-x. Epub 2016 Mar 15. Support Care Cancer. 2016. PMID: 26980330

7

Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).

Launay-Vacher V, Aapro M, De Castro G Jr, Cohen E, Deray G, Dooley M, Humphreys B, Lichtman S, Rey J, Scotté F, Wildiers H, Sprangers B. Launay-Vacher V, et al. Ann Oncol. 2015 Aug;26(8):1677-84. doi: 10.1093/annonc/mdv136. Epub 2015 Mar 3. Ann Oncol. 2015. PMID: 25735315 Free article. Review.

8

Intermittent dosing of aromatase inhibitors (AI) to improve tolerance in postmenopausal women: a rationale for future clinical studies.

Salmon R, Rey JB, Launay-Vacher V. Salmon R, et al. Cancer Chemother Pharmacol. 2015 Mar;75(3):653-5. doi: 10.1007/s00280-015-2690-2. Epub 2015 Jan 31. Cancer Chemother Pharmacol. 2015. PMID: 25637551

9

Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.

Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M; European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Launay-Vacher V, et al. Cancer Chemother Pharmacol. 2008 May;61(6):903-9. doi: 10.1007/s00280-008-0711-0. Epub 2008 Mar 4. Cancer Chemother Pharmacol. 2008. PMID: 18317762 Review.

10

[Antineoplastic drug induced nausea and vomiting: What is the clinical practice in 2018? An update of AFSOS clinical guidelines].

Jovenin N, Eche-Gass A, Chèze S, Launay-Vacher V, Mayeur D, Rey JB, Joly F, Krakowski I, Scotté F; Groupe de travail du référentiel Association francophone pour les soins oncologiques de support (AFSOS) sur les nausées-vomissements induits par les traitements anti-cancéreux. Jovenin N, et al. Among authors: launay vacher v. Bull Cancer. 2019 May;106(5):497-509. doi: 10.1016/j.bulcan.2019.02.002. Epub 2019 Mar 25. Bull Cancer. 2019. PMID: 30922554 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

177 results

Search Page

Filters